Department of Epidemiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, No. 16766, Jingshi Road, Ji'nan City, Shandong Province, 250000, People's Republic of China.
Infectious Diseases Center, The First Affiliated Hospital of Xinjiang Medical University, No.137, Liyushan South Road830000, Urumqi City, Xinjiang Province, People's Republic of China.
BMC Gastroenterol. 2022 Nov 9;22(1):452. doi: 10.1186/s12876-022-02541-1.
Patients with low HBV DNA levels (< 2000 IU/mL), HBV DNA negative, and HBsAg-negative hepatitis B virus(HBV)infection can still progress to decompensated cirrhosis; however, clinical research data in such patients, especially treatment-naïve patients, are currently insufficient. This study assessed the natural history of aforementioned patients.
We retrospectively reviewed the data of 250 patients with HBV-associated decompensated cirrhosis(HBV DNA < 2000 IU/mL) who had not been treated with antiviral medication.
The mean age of the 250 patients was 53.90 ± 11.73 years and 183 patients (73.2%) were male. HBV DNA, HBsAg, and HBeAg positivity was detected in 77 (30.8%), 200 (80%), and 137 (54.8%) patients, respectively. HBsAg (odds ratio [OR], 3.303; 95% confidence interval [CI], 1.338-8.152; P = 0.010) and HBeAg (OR, 0.200; 95% CI, 0.107-0.376; P < 0.001) positivity were independent factors for low HBV DNA levels. The incidence of hepatocellular carcinoma (HCC) (P < 0.001) and portal vein thrombosis (P = 0.001) was higher in the low HBV DNA levels group. Multivariate analysis showed that HBV DNA positivity (OR, 3.548; 95% CI, 1.463-8.604; P = 0.005), HBeAg positivity (OR, 0.080; 95% CI, 0.022-0.289; P < 0.001), and glutamyltransferase (GGT) (OR, 1.003; 95% CI, 1.000-1.006; P = 0.040) were independent factors for HCC. Age was not related to the occurrence of cirrhosis complications.
Patients with decompensated cirrhosis with HBV DNA < 2000 IU/mL still had severe liver damage and could develop severe cirrhosis complications. HCC risk was higher in low HBV DNA levels patients. HBsAg positivity and HBeAg negativity may be associated to the occurrence of low HBV DNA levels.
HBV DNA 水平<2000IU/ml、HBV DNA 阴性和 HBsAg 阴性的乙型肝炎病毒(HBV)感染患者仍可能进展为失代偿性肝硬化;然而,目前针对此类患者(尤其是初治患者)的临床研究数据尚不充分。本研究评估了上述患者的自然史。
我们回顾性分析了 250 例未接受抗病毒治疗的 HBV 相关失代偿性肝硬化(HBV DNA<2000IU/ml)患者的数据。
250 例患者的平均年龄为 53.90±11.73 岁,183 例(73.2%)为男性。77 例(30.8%)、200 例(80%)和 137 例(54.8%)患者的 HBV DNA、HBsAg 和 HBeAg 阳性率分别为 77(30.8%)、200(80%)和 137(54.8%)。HBsAg(比值比[OR],3.303;95%置信区间[CI],1.338-8.152;P=0.010)和 HBeAg(OR,0.200;95%CI,0.107-0.376;P<0.001)阳性是低 HBV DNA 水平的独立因素。低 HBV DNA 水平组肝细胞癌(HCC)(P<0.001)和门静脉血栓形成(P=0.001)的发生率较高。多变量分析显示 HBV DNA 阳性(OR,3.548;95%CI,1.463-8.604;P=0.005)、HBeAg 阳性(OR,0.080;95%CI,0.022-0.289;P<0.001)和谷氨酰转肽酶(GGT)(OR,1.003;95%CI,1.000-1.006;P=0.040)是 HCC 的独立因素。年龄与肝硬化并发症的发生无关。
HBV DNA<2000IU/ml 的失代偿性肝硬化患者仍有严重的肝损伤,并可能发生严重的肝硬化并发症。HBV DNA 水平较低的患者 HCC 风险更高。HBsAg 阳性和 HBeAg 阴性可能与低 HBV DNA 水平的发生有关。